Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 14:2019:1609717.
doi: 10.1155/2019/1609717. eCollection 2019.

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Affiliations

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Jingyuan Yang et al. J Ophthalmol. .

Abstract

The purpose of this study was to compare 6-year visual outcomes of antivascular endothelial growth factor (anti-VEGF) monotherapy and initial combination therapy of photodynamic therapy (PDT) and anti-VEGF therapy for polypoidal choroidal vasculopathy (PCV) in a Chinese population and to investigate imaging biomarkers associated with visual outcomes. Forty-eight treatment-naive PCV eyes of 46 patients were reviewed retrospectively, which underwent anti-VEGF monotherapy or initial combination therapy. PCV was classified into 2 subtypes. Mean best-corrected visual acuity (BCVA) using logarithm of minimal angle resolution and imaging morphological features was compared. No significant differences of mean BCVA changes were noticed between anti-VEGF monotherapy and combination therapy in either subtype 1 PCV or subtype 2 PCV during 6-year period (all P values >0.05). Compared with BCVA at baseline, the mean BCVA at 72 months deteriorated significantly in eyes with subtype 1 PCV (P < 0.001), while the mean BCVA at 72 months remained stable in eyes with subtype 2 PCV (P=0.941). In subtype 2 PCV eyes with continuous retina pigment epithelium, the mean changes of BCVA in eyes treated with anti-VEGF monotherapy were better than those in eyes treated with combination therapy (P=0.020). Anti-VEGF monotherapy and combination therapy for various subtypes of PCV had comparable long-term visual outcomes in most cases in real world. Imaging biomarkers which correlate with visual outcomes and treatment response should be included in the classification of PCV and validated in real world.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Mean (95% confidence interval) changes of best-corrected visual acuity (BCVA) from baseline using logMAR over 72 months after antivascular endothelial growth factor (VEGF) monotherapy or combination therapy of photodynamic therapy and anti-VEGF therapy for polypoidal choroidal vasculopathy (PCV). The subtype 2 PCV had better mean changes of BCVA than the subtype 1 PCV since month 12 (P < 0.05).

References

    1. Yannuzzi L. A., Sorenson J., Spaide R. F., Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV) Retina. 1990;10(1):1–8. doi: 10.1097/00006982-199010010-00001. - DOI - PubMed
    1. Koh A. H. C., Chen L.-J., Chen S.-J., et al. Polypoidal choroidal vasculopathy. Retina. 2013;33(4):686–716. doi: 10.1097/IAE.0b013e3182852446. - DOI - PubMed
    1. Oishi A., Kojima H., Mandai M., et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. American Journal of Ophthalmology. 2013;156(4):644–651. doi: 10.1016/j.ajo.2013.05.024. - DOI - PubMed
    1. Wong T. Y., Ogura Y., Lee W. K., et al. Efficacy and safety of intravitreal Aflibercept for polypoidal choroidal vasculopathy: two-year results of the Aflibercept in polypoidal choroidal vasculopathy study. American Journal of Ophthalmology. 2019;204:80–89. doi: 10.1016/j.ajo.2019.02.027. - DOI - PubMed
    1. Takahashi K., Ohji M., Terasaki H., et al. Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study. Clinical Ophthalmology. 2018;Volume 12:1789–1799. doi: 10.2147/opth.S171015. - DOI - PMC - PubMed

LinkOut - more resources